Activity of Nivolumab Among Patients With Recurrent Atypical/Anaplastic Meningioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Activity of PD-1 Blockade With Nivolumab Among Patients With Recurrent Atypical/Anaplastic Meningioma: Phase II Trial Results
Neuro-oncology 2021 May 20;[EPub Ahead of Print], WL Bi, L Nayak, DM Meredith, J Driver, Z Du, S Hoffman, Y Li, EQ Lee, R Beroukhim, M Rinne, R McFaline-Figueroa, U Chukwueke, C McCluskey, S Gaffey, AD Cherniack, J Stefanik, L Doherty, C Taubert, M Cifrino, D LaFrankie, T Graillon, PY Wen, KL Ligon, O Al-Mefty, RY Huang, A Muzikansky, EA Chiocca, S Santagata, IF Dunn, DA ReardonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.